References 

1. Prakash H, Chakrabarti A. Epidemiology of mucormycosis in India. Microorganisms. 2021;9(3):112. doi: 10.3390/microorganisms9030523, PMID 33806386.

2. Challa S. Mucormycosis: pathogenesisand pathology. Curr Fungal Infect 2019;13(1):11-20. doi: 10.1007/s12281-019-0337-1.

3. Technical guidelines on diagnosis and treatment of COVID-19 associated mucormycosis. of Kerala, No. 28/31; May2021. F2/2020/H&FW-16[cited 1/7/2021]. Available from: https://health.kerala.gov.in/pdf/Guidelines_Mucormycosis_management.pdf.

4. Shevade S. Mucormycosis: blackfungus, A deadly post-COVID Mar microbiol.2021;2:5.

5. Corticosteroids for COVID-19. living guidance 2020September 2 [cited 1/7/2021]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1.

6. Clinical guidance for management of adult Covid-19 patients; 2021 May 17 [cited 1/7/2021]. Available from: https://covid.aiims.edu/clinical-guidance-for-management-of-adult-covid-19-patients/.

7. Statement on Casirivimabplus Imdevimab EUA; 2021 June 3 [cited 1/7/2021]. Available from: https://www.covid19treatmentguidelines.nih.gov/.